ArriVent BioPharma (AVBP) Preferred Stock Liabilities (2023)
ArriVent BioPharma (AVBP) reported Preferred Stock Liabilities of $149.9 million for Q4 2023, little changed sequentially from $149.9 million in Q3 2023.
ArriVent BioPharma (AVBP) Preferred Stock Liabilities (2023) Analysis & Trends
ArriVent BioPharma (AVBP) has 1 years of Preferred Stock Liabilities data on file, last reported at $149.9 million in Q4 2023.
- For the quarter ending Q4 2023, Preferred Stock Liabilities changed N/A year-over-year to $149.9 million; the trailing twelve-month figure through Dec 2023 stood at $149.9 million (changed N/A YoY), and the FY2023 full-year result was $149.9 million, changed N/A from the prior year.
- Preferred Stock Liabilities steadied at $149.9 million in Q4 2023, from $149.9 million in the prior quarter.
- In the past five years, Preferred Stock Liabilities ranged from a high of $154.6 million in Q2 2023 to a low of $149.9 million in Q1 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | - |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | ArriVent BioPharma | 1.42 Bn | 1.42 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | 149.87 Mn |
| Sep 30, 2023 | 149.87 Mn |
| Jun 30, 2023 | 154.63 Mn |
| Mar 31, 2023 | 149.87 Mn |